Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18036125 | 0.85 | SMN1; SMN2 (0.46) | CYP2C19SMN1; SMN2ALDH1A1CRHBPCRHR2 | |
| SCHEMBL856718 | 0.83 | MAPT (0.61) | SMN1; SMN2KMT2AMAPTCYP1A2CYP2D6 | |
| SCHEMBL27508637 | 0.81 | MAPT (0.44) | CYP2C19SMN1; SMN2KMT2AMAPTCYP1A2 | |
| SCHEMBL28798344 | 0.81 | CRHBP (0.65) | CYP2C19SMN1; SMN2KMT2AMAPTCYP1A2 | |
| SCHEMBL18595209 | 0.81 | CYP2C19 (0.59) | CYP2C19SMN1; SMN2KMT2AMAPTCYP1A2 | |
| SCHEMBL29997984 | 0.80 | L3MBTL1 (0.51) | CYP2C19SMN1; SMN2MAPTCYP1A2L3MBTL1 | |
| SCHEMBL17827837 | 0.80 | L3MBTL1 (0.51) | CYP2C19SMN1; SMN2MAPTCYP1A2L3MBTL1 | |
| SCHEMBL856369 | 0.80 | PDE10A (0.46) | CYP2C19SMN1; SMN2KMT2AMAPTCYP1A2 | |
| SCHEMBL15938813 | 0.79 | CYP2C19 (0.56) | CYP2C19SMN1; SMN2KMT2AMAPTCYP1A2 | |
| SCHEMBL2531188 | 0.79 | KMT2A (0.68) | CYP2C19SMN1; SMN2KMT2AMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| CN-101801962-A | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB | 2010-08-11 | — | — | CN | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | CYP2C19 3775/4885SMN1; SMN2 3893/4885KMT2A 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.